ArticleAmerican journal of cancer research2023
The mechanism of long-chain acyl-CoA synthetase 3 in inhibiting cell proliferation, migration, and invasion in clear cell renal cell carcinoma.
Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- ACSL4 in Alzheimer's disease: Pathogenetic mechanisms and potential therapeutic targets.Genes & diseases · 2026Review
- The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling.Clinical and translational medicine · 2026Review
- Long-chain acyl-CoA synthetases: biological functions, diseases and therapeutic targets.Molecular biomedicine · 2025Review
- Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting.Molecular cancer · 2025Review
- Identification and Experimental Validation of Prognostic Signature and Peroxisome-Related Key Genes in Clear Cell Renal Cell Carcinoma.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-chain acyl-CoA synthases 3 (ACSL3) can activate long-chain fatty acids, which are often deregulated in tumors. However, the biological function of ACSL3 in clear cell renal cell carcinoma (ccRCC) is still unclear. In this research, the expression level, prognostic value, GO and KEGG functional enrichment analyses, genomic changes, clinical significance, immune infiltration of ACSL3 in ccRCC were comprehensively analysed. The expression levels of ACSL3 in ccRCC tissues were detected by quantitative reverse transcription-polymerase chain reaction (RT-qPCR), immunohistochemical staining (IHC), and Western blotting analysis. The proliferation, invasion, migration, apoptotic and lipid synthesis abilities of ccRCC cells were assessed using the cell counting kit (CCK-8), clone formation, scratch assay, Transwell assay, flow cytometry and Oil Red O assay, respectively. The results showed that ACSL3 was obviously downregulated in ccRCC and significantly associated with poor prognosis and clinicopathological factors of ccRCC patients. Additionally, the functional enrichment analysis indicated that ACSL3 was mainly involved in lipid synthesis and metabolism. The result of immune infiltration analysis proved that ACSL3 might regulate the tumor microenvironment of ccRCC. In addition, we demonstrated that overexpression of the ACSL3 could inhibit the proliferation, migration, and invasion of ccRCC cells, and promote apoptosis, reduce abnormal lipid accumulation. In conclusion, ACSL3 might be a novel ccRCC biomarker and the target for ccRCC tumor therapy.
Indexed as
Identifiers
37034217PMC10077045W4363646819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.